Peroxiredoxin-3 is overexpressed in prostate cancer and promotes cancer cell survival by protecting cells from oxidative stress

British Journal of Cancer

Volumn 109, Issue 4, 2013, Pages 983-993

  Whitaker, H C ^a   Patel, D ^a   Howat, W J ^b   Warren, A Y ^c   Kay, J D ^a   Sangan, T ^c   Marioni, J C ^d,e   Mitchell, J ^b   Aldridge, S ^f,g   Luxton, H J ^a,h   Massie, C ^a,d   Lynch, A G ^d   Neal, D E ^a  

^a Uro Oncology Research Group   (United Kingdom)

^b Histopathology and in Situ Hybridisation Core Facility   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d Statistics and Computational Biology Group   (United Kingdom)

^e WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^f Genomics Core   (United Kingdom)

^g UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^h UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; HYDROGEN PEROXIDE; PEROXIREDOXIN 3; REACTIVE OXYGEN METABOLITE; TRICARBOXYLIC ACID;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL; CELL MEMBRANE; CELL PROTECTION; CELL STRAIN LNCAP; CELL SURVIVAL; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MITOCHONDRION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; MICROSCOPY, CONFOCAL; MITOCHONDRIA; OXIDATIVE STRESS; PEROXIREDOXIN III; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS;

EID: 84883144775     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.396     Document Type: Article

References (89)

1. Ambruso DR, Ellison MA, Thurman GW, Leto TL (2012) Peroxiredoxin 6 translocates to the plasma membrane during neutrophil activation and is required for optimal NADPH oxidase activity. Biochim Biophys Acta 1823(2): 306-315.
2. Araki M, Nanri H, Ejima K, Murasato Y, Fujiwara T, Nakashima Y, Ikeda M (1999) Antioxidant function of the mitochondrial protein SP-22 in the cardiovascular system. J Biol Chem 274(4): 2271-2278.
3. Aran M, Ferrero DS, Pagano E, Wolosiuk RA (2009) Typical 2-Cys peroxiredoxins-modulation by covalent transformations and noncovalent interactions. FEBS J 276(9): 2478-2493.
4. Basu A, Banerjee H, Rojas H, Martinez SR, Roy S, Jia Z, Lilly MB, De Leon M, Casiano CA (2011) Differential expression of peroxiredoxins in prostate cancer: consistent upregulation of PRDX3 and PRDX4. The Prostate 71(7): 755-765.
5. Besada V, Diaz M, Becker M, Ramos Y, Castellanos-Serra L, Fichtner I (2006) Proteomics of xenografted human breast cancer indicates novel targets related to tamoxifen resistance. Proteomics 6(3): 1038-1048.
6. Bevan CL (2005) Androgen receptor in prostate cancer: cause or cure? Trendsendocrinol metab 16(9): 395-397.
7. Brown KK, Eriksson SE, Arner ES, Hampton MB (2008) Mitochondrial peroxiredoxin 3 is rapidly oxidised in cells treated with isothiocyanates. Free Radic Biol Med 45(4): 494-502.
8. Busija DW, Gaspar T, Domoki F, Katakam PV, Bari F (2008) Mitochondrialmediated suppression of ROS production upon exposure of neurons to lethal stress: mitochondrial targeted preconditioning. Adv Drug Deliv Rev 60(13-14): 1471-1477.
9. Cairns JM, Dunning MJ, Ritchie ME, Russell R, Lynch AG (2008) BASH: a tool for managing BeadArray spatial artefacts. Bioinformatics 24(24): 2921-2922.
10. Cha MK, Suh KH, Kim IH (2009) Overexpression of peroxiredoxin I and thioredoxin1 in human breast carcinoma. J Exp Clin Cancer Res 28: 93.
11. Chang KP, Yu JS, Chien KY, Lee CW, Liang Y, Liao CT, Yen TC, Lee LY, Huang LL, Liu SC, Chang YS, Chi LM (2011) Identification of PRDX4 and P4HA2 as metastasis-Associated proteins in oral cavity squamous cell carcinoma by comparative tissue proteomics of microdissected specimens using iTRAQ technology. J Proteome Res 10(11): 4935-4947.
12. Chang XZ, Li DQ, Hou YF, Wu J, Lu JS, Di GH, Jin W, Ou ZL, Shen ZZ, Shao ZM (2007) Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer. Breast Cancer Res 9(6): R76.
13. Chen L, Na R, Gu M, Salmon AB, Liu Y, Liang H, Qi W, Van Remmen H, Richardson A, Ran Q (2008) Reduction of mitochondrial H2O2 by overexpressing peroxiredoxin 3 improves glucose tolerance in mice. Aging Cell 7(6): 866-878.
14. Chhipa RR, Lee KS, Onate S, Wu Y, Ip C (2009) Prx1 enhances androgen receptor function in prostate cancer cells by increasing receptor affinity to dihydrotestosterone. Mol Cancer Res 7(9): 1543-1552.
15. Cho YE, Singh TS, Lee HC, Moon PG, Lee JE, Lee MH, Choi EC, Chen YJ, Kim SH, Baek MC (2012) In-depth identification of pathways related to cisplatin-induced hepatotoxicity through an integrative method based on an informatics-Assisted label-free protein quantitation and microarray gene expression approach. Mol Cell Proteomics: MCP 11(1): M111 010884.
16. Choi JH, Kim TN, Kim S, Baek SH, Kim JH, Lee SR, Kim Jr. (2002) Overexpression of mitochondrial thioredoxin reductase and peroxiredoxin III in hepatocellular carcinomas. Anticancer Res 22(6A): 3331-3335.
17. Chua PJ, Lee EH, Yu Y, Yip GW, Tan PH, Bay BH (2010) Silencing the Peroxiredoxin III gene inhibits cell proliferation in breast cancer. Int J Oncol 36(2): 359-364.
18. Cox AG, Brown KK, Arner ES, Hampton MB (2008a) The thioredoxin reductase inhibitor auranofin triggers apoptosis through a Bax/Bakdependent process that involves peroxiredoxin 3 oxidation. Biochem Pharmacol 76(9): 1097-1109.
19. Cox AG, Peskin AV, Paton LN, Winterbourn CC, Hampton MB (2009) Redox potential and peroxide reactivity of human peroxiredoxin 3. Biochemistry 48(27): 6495-6501.
20. Cox AG, Pullar JM, Hughes G, Ledgerwood EC, Hampton MB (2008b) Oxidation of mitochondrial peroxiredoxin 3 during the initiation of receptor-mediated apoptosis. Free Rad Biol Med 44(6): 1001-1009.
21. De Simoni S, Goemaere J, Knoops B (2008) Silencing of peroxiredoxin 3 and peroxiredoxin 5 reveals the role of mitochondrial peroxiredoxins in the protection of human neuroblastoma SH-SY5Y cells toward MPP\+. Neurosci Lett 433(3): 219-224.
22. Dittmann LM, Danner A, Gronych J, Wolter M, Stuhler K, Grzendowski M, Becker N, Bageritz J, Goidts V, Toedt G, Felsberg J, Sabel MC, Barbus S, Reifenberger G, Lichter P, Tews B (2011) Downregulation of PRDX1 by promoter hypermethylation is frequent in 1p/19q-deleted oligodendroglial tumours and increases radio-And chemosensitivity of Hs683 glioma cells in vitro. Oncogene 31: 3409-3418.
23. Dunning MJ, Smith ML, Ritchie ME, Tavare S (2007) Beadarray: R classes and methods for Illumina bead-based data. Bioinformatics 23(16): 2183-2184.
24. Fogal V, Zhang L, Krajewski S, Ruoslahti E (2008) Mitochondrial/cell- surface protein p32/gC1qR as a molecular target in tumor cells and tumor stroma. Cancer Res 68(17): 7210-7218.
25. Friedlander TW, Ryan CJ (2012) Targeting the androgen receptor. Urol Clin North Am 39(4): 453-464.
26. Fujii J, Ikeda Y (2002) Advances in our understanding of peroxiredoxin, a multifunctional, mammalian redox protein. Redox Rep 7(3): 123-130.
27. Gao MC, Jia XD, Wu QF, Cheng Y, Chen FR, Zhang J (2011) Silencing Prx1 and/or Prx5 sensitizes human esophageal cancer cells to ionizing radiation and increases apoptosis via intracellular ROS accumulation. Acta Pharmacol Sin 32(4): 528-536.
28. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, Zhang J (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5(10): R80.
29. Giorgio M, Trinei M, Migliaccio E, Pelicci PG (2007) Hydrogen peroxide: a metabolic by-product or a common mediator of ageing signals? Nat Rev 8(9): 722-728.
30. Hall A, Karplus PA, Poole LB (2009) Typical 2-Cys peroxiredoxins- structures, mechanisms and functions. FEBS J 276(9): 2469-2477.
31. Hanschmann EM, Lonn ME, Schutte LD, Funke M, Godoy JR, Eitner S, Hudemann C, Lillig CH (2010) Both thioredoxin 2 and glutaredoxin 2 contribute to the reduction of the mitochondrial 2-Cys peroxiredoxin Prx3. J Biol Chem 285(52): 40699-40705.
32. He HC, Zhu JG, Chen XB, Chen SM, Han ZD, Dai QS, Ling XH, Fu X, Lin ZY, Deng YH, Qin GQ, Cai C, Chen JH, Zhong WD (2012) MicroRNA-23b downregulates peroxiredoxin III in human prostate cancer. FEBS Lett 586(16): 2451-2458.
33. Higuchi M, Kudo T, Suzuki S, Evans TT, Sasaki R, Wada Y, Shirakawa T, Sawyer JR, Gotoh A (2006) Mitochondrial DNA determines androgen dependence in prostate cancer cell lines. Oncogene 25(10): 1437-1445.
34. Hobisch A, Fritzer A, Comuzzi B, Fiechtl M, Malinowska K, Steiner H, Bartsch G, Culig Z (2006) The androgen receptor pathway is by-passed in prostate cancer cells generated after prolonged treatment with bicalutamide. Prostate 66(4): 413-420.
35. Hoskins ER, Hood BL, Sun M, Krivak TC, Edwards RP, Conrads TP (2011) Proteomic analysis of ovarian cancer proximal fluids: validation of elevated peroxiredoxin 1 in patient peripheral circulation. PLoS One 6(9): e25056.
36. Karihtala P, Kauppila S, Soini Y, Arja Jukkola V (2011) Oxidative stress and counteracting mechanisms in hormone receptor positive, triple-negative and basal-like breast carcinomas. BMC Cancer 11: 262.
37. Karihtala P, Mantyniemi A, Kang SW, Kinnula VL, Soini Y (2003) Peroxiredoxins in breast carcinoma. Clin Cancer Res 9(9): 3418-3424.
38. Kikuta K, Tochigi N, Saito S, Shimoda T, Morioka H, Toyama Y, Hosono A, Suehara Y, Beppu Y, Kawai A, Hirohashi S, Kondo T (2010) Peroxiredoxin 2 as a chemotherapy responsiveness biomarker candidate in osteosarcoma revealed by proteomics. Proteomics Clin Appl 4(5): 560-567.
39. Kim JH, Bogner PN, Baek SH, Ramnath N, Liang P, Kim HR, Andrews C, Park YM (2008) Up-regulation of peroxiredoxin 1 in lung cancer and its implication as a prognostic and therapeutic target. Clin Cancer Res 14(8): 2326-2333.
40. Kim K, Yu M, Han S, Oh I, Choi YJ, Kim S, Yoon K, Jung M, Choe W (2009) Expression of human peroxiredoxin isoforms in response to cervical carcinogenesis. Oncol Rep 21(6): 1391-1396.
41. Kinnula VL, Lehtonen S, Sormunen R, Kaarteenaho-Wiik R, Kang SW, Rhee SG, Soini Y (2002) Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma. J Pathol 196(3): 316-323.
42. Kuil CW, Mulder E (1994) Mechanism of antiandrogen action: conformational changes of the receptor. Mol Cell Endocrinol 102(1-2): R1-R5.
43. Kumar V, Kitaeff N, Hampton MB, Cannell MB, Winterbourn CC (2009) Reversible oxidation of mitochondrial peroxiredoxin 3 in mouse heart subjected to ischemia and reperfusion. FEBS Lett 583(6): 997-1000.
44. Lee KW, Lee DJ, Lee JY, Kang DH, Kwon J, Kang SW (2011) Peroxiredoxin II restrains DNA damage-induced death in cancer cells by positively regulating JNK-dependent DNA repair. J Biol Chem 286(10): 8394-8404.
45. Lee W, Wells T, Kantorow M (2007) Localization and H2O2-specific induction of PRDX3 in the eye lens. Mol Vis 13: 1469-1474.
46. Lehtonen ST, Svensk AM, Soini Y, Paakko P, Hirvikoski P, Kang SW, Saily M, Kinnula VL (2004) Peroxiredoxins, a novel protein family in lung cancer. Int J Cancer 111(4): 514-521.
47. Lenaz G (2012) Mitochondria and reactive oxygen species. Which role in physiology and pathology? Adv Exp Med Biol 942: 93-136.
48. Leyens G, Donnay I, Knoops B (2003) Cloning of bovine peroxiredoxins-gene expression in bovine tissues and amino acid sequence comparison with rat, mouse and primate peroxiredoxins. Comp BiochemPhysiol 136(4): 943-955.
49. Li KK, Pang JC, Lau KM, Zhou L, Mao Y, Wang Y, Poon WS, Ng HK (2012) MiR-383 is downregulated in medulloblastoma and targets Peroxiredoxin 3 (PRDX3). Brain Pathol 23: 413-425.
50. Lin H, Lu JP, Laflamme P, Qiao S, Shayegan B, Bryskin I, Monardo L, Wilson BC, Singh G, Pinthus JH (2010) Inter-related in vitro effects of androgens, fatty acids and oxidative stress in prostate cancer: a mechanistic model supporting prevention strategies. Int J Oncol 37(4): 761-766.
51. Lin JF, Xu J, Tian HY, Gao X, Chen QX, Gu Q, Xu GJ, Song JD, Zhao FK (2007) Identification of candidate prostate cancer biomarkers in prostate needle biopsy specimens using proteomic analysis. Int J Cancer 121(12): 2596-2605.
52. Liu L, Yang C, Yuan J, Chen X, Xu J, Wei Y, Yang J, Lin G, Yu L (2005) RPK118, a PX domain-containing protein, interacts with peroxiredoxin-3 through pseudo-kinase domains. Mol Cells 19(1): 39-45.
53. Massie CE, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L, Warren A, Scott H,Madhu B, Sharma N, Bon H, Zecchini V, Smith DM, Denicola GM, Mathews N, Osborne M, Hadfield J, Macarthur S, Adryan B, Lyons SK, Brindle KM, Griffiths J, Gleave ME, Rennie PS, Neal DE, Mills IG (2011) The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J 30(13): 2719-2733.
54. Maxwell GL, Hood BL, Day R, Chandran U, Kirchner D, Kolli VS, Bateman NW, Allard J, Miller C, Sun M, Flint MS, Zahn C, Oliver J, Banerjee S, Litzi T, Parwani A, Sandburg G, Rose S, Becich MJ, Berchuck A, Kohn E, Risinger JI, Conrads TP (2011) Proteomic analysis of stage I endometrial cancer tissue: identification of proteins associated with oxidative processes and inflammation. Gynecol Oncol 121(3): 586-594.
55. Miki H, Funato Y (2012) Regulation of intracellular signalling through cysteine oxidation by reactive oxygen species. J Biochem 151(3): 255-261.
56. Noh DY, Ahn SJ, Lee RA, Kim SW, Park IA, Chae HZ (2001) Overexpression of peroxiredoxin in human breast cancer. Anticancer Res 21(3B): 2085-2090.
57. Pak JH, Choi WH, Lee HM, Joo WD, Kim JH, Kim YT, Kim YM, Nam JH (2011) Peroxiredoxin 6 overexpression attenuates cisplatin-induced apoptosis in human ovarian cancer cells. Cancer Invest 29(1): 21-28.
58. Palande KK, Beekman R, van der Meeren LE, Beverloo HB, Valk PJ, Touw IP (2011) The antioxidant protein peroxiredoxin 4 is epigenetically down regulated in acute promyelocytic leukemia. PLoS ONE 6(1): e16340.
59. Park JH, Kim YS, Lee HL, Shim JY, Lee KS, Oh YJ, Shin SS, Choi YH, Park KJ, Park RW, Hwang SC (2006) Expression of peroxiredoxin and thioredoxin in human lung cancer and paired normal lung. Respirology 11(3): 269-275.
60. Park JY, Kim SA, Chung JW, Bang S, Park SW, Paik YK, Song SY (2011) Proteomic analysis of pancreatic juice for the identification of biomarkers of pancreatic cancer. J Cancer Res Clin Oncol 137(8): 1229-1238.
61. Park SY, Yu X, Ip C, Mohler JL, Bogner PN, Park YM (2007) Peroxiredoxin 1 interacts with androgen receptor and enhances its transactivation. Cancer Res 67(19): 9294-9303.
62. Pylvas M, Puistola U, Kauppila S, Soini Y, Karihtala P (2010) Oxidative stressinduced antioxidant enzyme expression is an early phenomenon in ovarian carcinogenesis. Eur J Cancer 46(9): 1661-1667.
63. Quan C, Cha EJ, Lee HL, Han KH, Lee KM, Kim WJ (2006) Enhanced expression of peroxiredoxin I and VI correlates with development, recurrence and progression of human bladder cancer. J Urol 175(4): 1512-1516.
64. Ray PD, Huang BW, Tsuji Y (2012) Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal 24(5): 981-990.
65. Ren L, Yang HY, Choi HI, Chung KJ, Yang U, Lee IK, Kim HJ, Lee DS, Park BJ, Lee TH (2011) The role of peroxiredoxin V in (-)-epigallocatechin 3-gallate-induced multiple myeloma cell death. Oncol Res 19(8-9): 391-398.
66. Ruckenstuhl C, Buttner S, Carmona-Gutierrez D, Eisenberg T, Kroemer G, Sigrist SJ, Frohlich KU, Madeo F (2009) The Warburg effect suppresses oxidative stress induced apoptosis in a yeast model for cancer. PLoS One 4(2): e4592.
67. Rustin P, Kroemer G (2007) Mitochondria and cancer. Ernst Schering Found Sym Proc 4: 1-21.
68. Shen C, Nathan C (2002) Nonredundant antioxidant defense by multiple two-cysteine peroxiredoxins in human prostate cancer cells. Mol Med 8(2): 95-102.
69. Shiota M, Yokomizo A, Kashiwagi E, Takeuchi A, Fujimoto N, Uchiumi T, Naito S (2011) Peroxiredoxin 2 in the nucleus and cytoplasm distinctly regulates androgen receptor activity in prostate cancer cells. Free Rad Biol Med 51(1): 78-87.
70. Smyth GK (2005) Limma: linear models for microarray data in R. Springer: New York.
71. Sofiadis A, Becker S, Hellman U, Hultin-Rosenberg L, Dinets A, Hulchiy M, Zedenius J, Wallin G, Foukakis T, Hoog A, Auer G, Lehtio J, Larsson C (2012) Proteomic profiling of follicular and papillary thyroid tumors. Eur J Endocrinol 166: 657-667.
72. SvendsenA,Verhoeff JJ, ImmervollH, Brogger JC, Kmiecik J, Poli A, Netland IA, Prestegarden L, Planaguma J, Torsvik A, Kjersem AB, Sakariassen PO, Heggdal JI, Van Furth WR, Bjerkvig R, Lund-Johansen M, Enger PO, Felsberg J, Brons NH, Tronstad KJ, Waha A, Chekenya M (2011) Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma. Acta Neuropathol 122(4): 495-510.
73. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15): 1502-1512.
74. Thongwatchara P, Promwikorn W, Srisomsap C, Chokchaichamnankit D, Boonyaphiphat P, Thongsuksai P (2011) Differential protein expression in primary breast cancer and matched axillary node metastasis. Oncol Rep 26(1): 185-191.
75. Trachootham D, Alexandre J, Huang P (2009) Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 8(7): 579-591.
76. Trachootham D, Lu W, Ogasawara MA, Nilsa RD, Huang P (2008) Redox regulation of cell survival. Antioxid Redox Signal 10(8): 1343-1374.
77. Ummanni R, Barreto F, Venz S, Scharf C, Barett C, Mannsperger HA, Brase JC, Kuner R, Schlomm T, Sauter G, Sultmann H, Korf U, Bokemeyer C, Walther R, Brummendorf TH, Balabanov S (2012) Peroxiredoxins 3 and 4 are overexpressed in prostate cancer tissue and affect the proliferation of prostate cancer cells in vitro. J Proteome Res 11(4): 2452-2466.
78. Vias M, Burtt G, Culig Z, Veerakumarasivam A, Neal DE, Mills IG (2006) A role for neurotensin in bicalutamide resistant prostate cancer cells. Prostate 67(2): 190-202.
79. Vivas-Mejia PE, Ozpolat B, Chen X, Lopez-Berestein G (2009) Downregulation of the c-MYC target gene, peroxiredoxin III, contributes to arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Int J Cancer 125(2): 264-275.
80. Whitaker HC, Girling J, Warren AY, Leung H, Mills IG, Neal DE (2008) Alterations in beta-catenin expression and localization in prostate cancer. Prostate 68(11): 1196-1205.
81. Whitaker HC, Kote-Jarai Z, Ross-Adams H, Warren AY, Burge J, George A, Bancroft E, Jhavar S, Leongamornlert D, Tymrakiewicz M, Saunders E, Page E, Mitra A, Mitchell G, Lindeman GJ, Evans DG, Blanco I, Mercer C, Rubinstein WS, Clowes V, Douglas F, Hodgson S, Walker L, Donaldson A, Izatt L, Dorkins H, Male A, Tucker K, Stapleton A, Lam J, Kirk J, Lilja H, Easton D, Cooper C, Eeles R, Neal DE (2010) The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine. PLoS One 5(10): e13363.
82. Whitaker HC, Stanbury DP, Brinham C, Girling J, Hanrahan S, Totty N, Neal DE (2007) Labeling and identification of LNCaP cell surface proteins: a pilot study. Prostate 67(9): 943-954.
83. Wonsey DR, Zeller KI, Dang CV (2002) The c-Myc target gene PRDX3 is required for mitochondrial homeostasis and neoplastic transformation. Proc Natl Acad Sci USA 99(10): 6649-6654.
84. Wood ZA, Schroder E, Robin Harris J, Poole LB (2003) Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci 28(1): 32-40.
85. Woolston CM, Storr SJ, Ellis IO, Morgan DA, Martin SG (2011) Expression of thioredoxin system and related peroxiredoxin proteins is associated with clinical outcome in radiotherapy treated early stage breast cancer. Radiother Oncol 100(2): 308-313.
86. Zhang B, Wang K, He G, Guan X, Liu B, Liu Y, Bai Y (2012) Polymorphisms of peroxiredoxin 1, 2 and 6 are not associated with esophageal cancer. J Cancer Res Clin Oncol 138: 621-626.
87. Zhang B, Wang Y, Su Y (2009) Peroxiredoxins, a novel target in cancer radiotherapy. Cancer Lett 286(2): 154-160.
88. Zhang J, Wang K, Liu SS, Dai L, Zhang JY (2011) Using proteomic approach to identify tumor-Associated proteins as biomarkers in human esophageal squamous cell carcinoma. J Proteome Res 10(6): 2863-2872.
89. Zhiyu W, Yue C, Neng W, Mei WD, Wei LY, Feng H, Gang SJ, De PoY, Yuan GX, Jian-Ping C (2012) Dioscin induces cancer cell apoptosis through elevated oxidative stress mediated by downregulation of peroxiredoxins. Cancer Biol Ther 13(3): 138-147.